Jeffrey A. Meckler
CEO and Director at Indaptus Therapeutics Inc.
Sits on 2 boards. Last updated September 28, 2026
Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 7 years
- Director since
- 2023
7 years of board service in total across 2 boards, counting each seat separately. Longest: Indaptus Therapeutics Inc., 3 years.
Chief executive roles
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Travere Therapeutics Inc. May 19, 202696.9%
-
Travere Therapeutics Inc. May 15, 202596.2%
-
Indaptus Therapeutics Inc. June 6, 202492.8%
-
Travere Therapeutics Inc. May 8, 202495.2%
-
Travere Therapeutics Inc. May 17, 202394.3%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 10, 2026 | Travere Therapeutics Inc. | Option exercise | +10,000 | $17.44 | $174,400 |
| Sep 10, 2026 | Travere Therapeutics Inc. | Option exercise | +10,000 | $26.52 | $265,200 |
| Sep 10, 2026 | Travere Therapeutics Inc. | Open-market sale | −1,700 | $65.39 | $111,163 |
| Sep 10, 2026 | Travere Therapeutics Inc. | Open-market sale | −1,200 | $66.15 | $79,380 |
| Sep 10, 2026 | Travere Therapeutics Inc. | Open-market sale | −14,000 | $67.46 | $944,440 |
| Sep 10, 2026 | Travere Therapeutics Inc. | Open-market sale | −3,100 | $68.09 | $211,079 |
| May 19, 2026 | Travere Therapeutics Inc. | Grant or award | +4,000 | — | — |
| May 4, 2026 | Travere Therapeutics Inc. | Option exercise | +8,000 | $16.33 | $130,640 |
| May 4, 2026 | Travere Therapeutics Inc. | Open-market sale | −8,000 | $45.00 | $360,000 |
| Dec 22, 2025 | Indaptus Therapeutics Inc. | Grant or award | +216,617 | $2.03 | $439,733 |
| Jul 27, 2025 | Indaptus Therapeutics Inc. | Grant or award | +6,068 | $8.30 | $50,364 |
| May 15, 2025 | Travere Therapeutics Inc. | Grant or award | +6,500 | — | — |
| Nov 25, 2024 | Indaptus Therapeutics Inc. | Grant or award | +42,553 | $1.18 | $50,213 |
| Sep 30, 2024 | Travere Therapeutics Inc. | Option exercise | +40,000 | $10.48 | $419,200 |
| Sep 30, 2024 | Travere Therapeutics Inc. | Open-market sale | −40,000 | $14.06 | $562,400 |
Questions about Jeffrey A. Meckler
What boards is Jeffrey A. Meckler on?
Jeffrey A. Meckler sits on the boards of Indaptus Therapeutics Inc. and Travere Therapeutics Inc.
What company is Jeffrey A. Meckler the CEO of?
Jeffrey A. Meckler is CEO and Director of Indaptus Therapeutics Inc.
How long has Jeffrey A. Meckler served on boards?
Our records show at least 7 years of board service across 2 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.